TY - JOUR
T1 - The Treatment of Peri-Implant Diseases: A New Approach Using HYBENX® as a Decontaminant for Implant Surface and Oral Tissues
AU - Lopez, Michele Antonio
AU - Passarelli, Pier Carmine
AU - Godino, Emmanuele
AU - Lombardo, Nicolò
AU - Altamura, Francesca Romana
AU - Speranza, Alessandro
AU - Lopez, Andrea
AU - Papi, Piero
AU - Pompa, Giorgio
AU - D'Addona, Antonio
PY - 2021
Y1 - 2021
N2 - Background: Peri-implantitis is a pathological condition characterized by an inflammatory process involving soft and hard tissues surrounding dental implants. The management of peri-implant disease has several protocols, among which is the chemical method HYBENX(R). The aim of this study is to demonstrate the efficacy of HYBENX(R) in the treatment of peri-implantitis and to compare HYBENX(R) with other chemical agents used in the surgical treatment of peri-implantitis. Methods: The present study included a population of ten subjects with severe peri-implantitis. The procedure used in the study involves the application of HYBENX(R) after open-flap debridement. Each patient has been followed for 12 months after a single application of the decontaminant agent. Clinical and radiographical parameters were recorded at baseline, 3 months, and 12 months after treatment completion. Results: At baseline, a mean pocket probing depth (PPD) of 7.3 +/- 0.5 mm and a mean clinical attachment level (CAL) of 8.8 +/- 0.8 mm was recorded. An average residual PPD of 4.2 +/- 0.5 mm and a mean CAL of 5.2 +/- 0.8 mm were observed after 1 year. Additionally, the average of bone gain was about 3.4 mm, with a mean marginal bone level (MBL) change from 5.8 mm (baseline) to 2.4 mm (12 months). In total, 90% of the treated implants reached the success rate after the 1-year follow-up. Only in one case out of ten treated implants was resolution of the disease not achieved. Conclusion: Clinical improvements highlight that the procedure of open-flap debridement (OFD) + HYBENX(R) may be considered an effective technique in the treatment of peri-implantitis. From the results obtained, it can be concluded that the use of HYBENX(R) in the surgical treatment of peri-implantitis is promising. Overall, this protocol demands further studies to better understand the role and potential benefits of HYBENX(R) in the treatment of peri-implantitis.
AB - Background: Peri-implantitis is a pathological condition characterized by an inflammatory process involving soft and hard tissues surrounding dental implants. The management of peri-implant disease has several protocols, among which is the chemical method HYBENX(R). The aim of this study is to demonstrate the efficacy of HYBENX(R) in the treatment of peri-implantitis and to compare HYBENX(R) with other chemical agents used in the surgical treatment of peri-implantitis. Methods: The present study included a population of ten subjects with severe peri-implantitis. The procedure used in the study involves the application of HYBENX(R) after open-flap debridement. Each patient has been followed for 12 months after a single application of the decontaminant agent. Clinical and radiographical parameters were recorded at baseline, 3 months, and 12 months after treatment completion. Results: At baseline, a mean pocket probing depth (PPD) of 7.3 +/- 0.5 mm and a mean clinical attachment level (CAL) of 8.8 +/- 0.8 mm was recorded. An average residual PPD of 4.2 +/- 0.5 mm and a mean CAL of 5.2 +/- 0.8 mm were observed after 1 year. Additionally, the average of bone gain was about 3.4 mm, with a mean marginal bone level (MBL) change from 5.8 mm (baseline) to 2.4 mm (12 months). In total, 90% of the treated implants reached the success rate after the 1-year follow-up. Only in one case out of ten treated implants was resolution of the disease not achieved. Conclusion: Clinical improvements highlight that the procedure of open-flap debridement (OFD) + HYBENX(R) may be considered an effective technique in the treatment of peri-implantitis. From the results obtained, it can be concluded that the use of HYBENX(R) in the surgical treatment of peri-implantitis is promising. Overall, this protocol demands further studies to better understand the role and potential benefits of HYBENX(R) in the treatment of peri-implantitis.
KW - HYBENX
KW - decontamination
KW - implant dentistry
KW - mucositis
KW - oral surgery
KW - peri-implantitis
KW - HYBENX
KW - decontamination
KW - implant dentistry
KW - mucositis
KW - oral surgery
KW - peri-implantitis
UR - https://publicatt.unicatt.it/handle/10807/232208
UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85105959105&origin=inward
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85105959105&origin=inward
U2 - 10.3390/antibiotics10050512
DO - 10.3390/antibiotics10050512
M3 - Article
SN - 2079-6382
VL - 10
SP - 512-N/A
JO - Antibiotics
JF - Antibiotics
IS - 5
ER -